科研之友
微信
新浪微博
Facebook
分享链接
摘要
The for the most part long preclinical stages, the large variability of clinical manifestations as well as the need of an early adequate therapy of autoimmune diseases require the search for and evaluation of applicable biomarkers, which reliably reflect the disease process and allow for a definite early diagnosis as well as for therapeutically relevant evidence (disease activity and course, organ manifestations, reliability of different types of therapy). To date, mainly autoantibodies have been used for serological diagnostics, prognostics and partially also for monitoring of autoimmune diseases. Dependent on the diagnostic variables they are important diagnostic markers but the usefulness for prognostics, theranostics and disease monitoring is rather low. Therefore, the purpose of future developments should be to find adequate combinations of disease relevant autoantibodies and other biomarkers to realize a reliable early diagnosis as well as to obtain useful information regarding clinical course and reliability of different types of therapy. Such multiparametric analyses are the prerequisite for an optimized personalized therapy and therefore for the improvement of the medical care of patients with autoimmune diseases.
- 出版日期2011
